Mark Elliott Boulding, Executive VP AND CLO at PTC THERAPEUTICS, INC. (PTCT), sold 150,840 shares at $53.15 ($8.0M) on 2025-03-10, disclosed to the SEC on 2025-03-12.
Scheduled sale ($8.0M) by Executive VP AND CLO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $52.24 | 3,487 | $182K | 2.3% |
| 2 | $52.24 | 3,487 | $182K | 2.3% |
| 3 | $53.05 | 7,762 | $412K | 5.1% |
| 4 | $53.05 | 7,762 | $412K | 5.1% |
| 5 | $53.12 | 11,398 | $605K | 7.6% |
| 6 | $53.12 | 11,398 |
| $605K |
| 7.6% |
| 7 | $53.15 | 45,392 | $2.4M | 30.1% |
| 8 | $53.15 | 45,392 | $2.4M | 30.1% |
| 9 | $53.01 | 1,719 | $91K | 1.1% |
| 10 | $53.01 | 1,719 | $91K | 1.1% |
| 11 | $53.02 | 5,662 | $300K | 3.7% |
| 12 | $53.02 | 5,662 | $300K | 3.7% |
| Total | $53.08 avg | 150,840 | $8.0M | 100% |
| Filing → |
| PTCT | SELL | 2026-08-19 | $204K | — | Filing → |
| PTCT | SELL | 2026-07-08 | $432K | — | Filing → |
| PTCT | SELL | 2026-06-22 | $823K | — | Filing → |